A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies

NCT01202370 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Solid Malignancies

Interventions

DRUG: 7-t-butyldimethylsilyl-10-hydroxycamptothecin

Sponsor

University of Kentucky

Collaborators

[object Object]